FIGURE 4 from Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies

B7-H3 expression and immune cell landscape. Immune cell deconvolution using quanTIseq demonstrates differences in cell fraction of T cells CD8+ (A), macrophage M1 (B), and macrophage M2 (C) across 10 different cancer types with high and low B7-H3 expression. *, q < 0.05; **, q < 0.01; ***, q < 0.001.